Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial

doi:10.2196/resprot.4042

JMIR Publications

JMIR Research Protocols

Browse by Year:

Browse:
Issues
Authors
Themes

Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Readers: No access to all 28 journals. We recommend accessing our articles via PubMed Central
Authors: No access to the submission form or your user account.
Reviewers: No access to your user account. Please download manuscripts you are reviewing for offline reading before Wednesday, July 01, 2020 at 7:00 PM.
Editors: No access to your user account to assign reviewers or make decisions.
Copyeditors: No access to user account. Please download manuscripts you are copyediting before Wednesday, July 01, 2020 at 7:00 PM.

JMIR Research Protocols

Published on 18.02.15 in Vol 4, No 1 (2015): Jan-Mar

This paper is in the following e-collection/theme issue:

Tweetations for "Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial"

Ashish Atreja, Sameer Khan, Jason D Rogers, Emamuzo Otobo, Nishant P Patel, Thomas Ullman, Jean Fred Colombel, Shirley Moore, Bruce E Sands, HealthPROMISE Consortium Group

JMIR Res Protoc 2015 (Feb 18); 4(1):e23

Tweets 1 - 2 of 2.

Tweets 1 - 2 of 2. 1

JMIR Research Protocols

Citing this Article

Published on 18.02.15 in Vol 4, No 1 (2015): Jan-Mar

This paper is in the following e-collection/theme issue:

Tweetations for "Impact of the Mobile HealthPROMISE Platform on the Quality of Care and Quality of Life in Patients With Inflammatory Bowel Disease: Study Protocol of a Pragmatic Randomized Controlled Trial"

Tweets 1 - 2 of 2.